Gregory L. Huson

Array ( [id] => 20192308 [patent_doc_number] => 20250269018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => COMBINED CANCER THERAPY WITH AN EPITHELIAL CELL ADHESION MOLECULE (EPCAM) INHIBITOR AND A HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR) INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/573623 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20437499 [patent_doc_number] => 12508321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers [patent_app_type] => utility [patent_app_number] => 17/835419 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 42477 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18347613 [patent_doc_number] => 20230135723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/806037 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 177871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20413088 [patent_doc_number] => 12496351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers [patent_app_type] => utility [patent_app_number] => 17/835311 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 42783 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20356286 [patent_doc_number] => 12472265 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers [patent_app_type] => utility [patent_app_number] => 17/835041 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 42676 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20262982 [patent_doc_number] => 12433950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers [patent_app_type] => utility [patent_app_number] => 17/835395 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 43908 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 429 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19909303 [patent_doc_number] => 12285491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-29 [patent_title] => Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers [patent_app_type] => utility [patent_app_number] => 17/835081 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 42479 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17835081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20393241 [patent_doc_number] => 20250368716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => DELTA T-CELL OR GAMMA T-CELL RECEPTOR CHAINS OR PARTS THEREOF THAT MEDIATE AN ANTI-TUMOUR OR ANTI-INFECTIVE RESPONSE [patent_app_type] => utility [patent_app_number] => 18/568179 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18362413 [patent_doc_number] => 20230144004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 17/830781 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20336496 [patent_doc_number] => 20250340616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => NOVEL PEPTIDE MIMICS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/565905 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18565905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986481 [patent_doc_number] => 20240058450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same [patent_app_type] => utility [patent_app_number] => 17/804696 [patent_app_country] => US [patent_app_date] => 2022-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 123027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17804696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895441 [patent_doc_number] => 20220305103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => CORE/SHELL STRUCTURE PLATFORM FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/751812 [patent_app_country] => US [patent_app_date] => 2022-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18335710 [patent_doc_number] => 20230127659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/749953 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51948 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091410 [patent_doc_number] => 20220409751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical [patent_app_type] => utility [patent_app_number] => 17/749763 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865353 [patent_doc_number] => 20220288088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/746205 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248767 [patent_doc_number] => 20240199754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => Applications of GHR-106 Monoclonal Antibody as a GnRH Antagonist [patent_app_type] => utility [patent_app_number] => 18/286895 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18184213 [patent_doc_number] => 20230044943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => Pharmaceutical Combinations [patent_app_type] => utility [patent_app_number] => 17/745136 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300027 [patent_doc_number] => 20240228596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => PAN-SPECIFIC CORONA VIRUS BINDERS [patent_app_type] => utility [patent_app_number] => 18/559915 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945712 [patent_doc_number] => 20220332729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES [patent_app_type] => utility [patent_app_number] => 17/733974 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19042347 [patent_doc_number] => 11931420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) [patent_app_type] => utility [patent_app_number] => 17/733327 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 37436 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733327 [rel_patent_id] =>[rel_patent_doc_number] =>)